Refractory Hodgkin Lymphoma
Some patients still have cancer cells in their bone marrow after Hodgkin lymphoma treatment. The term refractory Hodgkin lymphoma is used to describe a disease that doesn't go into remission (but may be stable) or that gets worse within six months of the last treatment.
If you have refractory Hodgkin lymphoma, you may undergo high-dose chemotherapy with stem cell transplantation.
Relapsed Hodgkin Lymphoma
If the lymphoma in your bone marrow returns and your normal blood cells decrease after a remission of six months or more, you've relapsed. You'll need more chemotherapy similar to what you received when you were newly diagnosed. The treatment often gives patients very long disease-free periods, and the disease is still potentially curable.
Brentuximab vedotin, (Adcetris®), is FDA approved for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not candidates for ASCT. Brentuximab vedotin is administered by injection.